Liposomes as nanovaccine delivery systems

Curr Top Med Chem. 2014;14(9):1194-208. doi: 10.2174/1568026614666140329232757.

Abstract

Since the discovery of liposomes by Alec Bangham in mid-1960s, these phospholipid vesicles have been widely used as pharmaceutical carriers. Liposomes have been extensively studied in the vaccine delivery field as a carrier and an immune stimulating agent. Liposomes are usually formulated as nanoparticles, mimicking the properties of pathogens, and have the ability to induce humoral and cell-mediated immune responses. In this review, we focused on modern nanotechnology-based approaches for the improvement of liposomal vaccine delivery systems. Topics such as size-dependent uptake, processing and activation of antigen presenting cells, targeting liposomes and route of administration are discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drug Carriers / administration & dosage
  • Drug Carriers / chemistry*
  • Humans
  • Liposomes / administration & dosage*
  • Nanomedicine*
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry*
  • Vaccines / administration & dosage*
  • Vaccines / chemistry
  • Vaccines / immunology*

Substances

  • Drug Carriers
  • Liposomes
  • Vaccines